ReviewHearing research2011
Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research.
Review in Hearing research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Stem Cells and Gene Therapy in Progressive Hearing Loss: the State of the Art.Journal of the Association for Research in Otolaryngology : JARO · 2021Review
- Review
- Bilateral Vestibular Weakness.Frontiers in neurology · 2018Review
- Rhesus Cochlear and Vestibular Functions Are Preserved After Inner Ear Injection of Saline Volume Sufficient for Gene Therapy Delivery.Journal of the Association for Research in Otolaryngology : JARO · 2017Article
- Biological therapies in otology.HNO · 2017Review
- Article
- Can the Video Head Impulse Test Define Severity of Bilateral Vestibular Hypofunction?Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology · 2017Article
- Persistence, distribution, and impact of distinctly segmented microparticles on cochlear health following in vivo infusion.Journal of biomedical materials research. Part A · 2016Article
- Optimizing atoh1-induced vestibular hair cell regeneration.The Laryngoscope · 2014Article
- Review
- Mouse otocyst transuterine gene transfer restores hearing in mice with connexin 30 deletion-associated hearing loss.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Gene transfer in inner ear cells: a challenging race.Gene therapy · 2013Review
- Gene therapy for the inner ear.Hearing research · 2013Review
- The cochlear implant: historical aspects and future prospects.Anatomical record (Hoboken, N.J. : 2007) · 2012Review
- Understanding the evolution and development of neurosensory transcription factors of the ear to enhance therapeutic translation.Cell and tissue research · 2012Review
- Probing the Xenopus laevis inner ear transcriptome for biological function.BMC genomics · 2012Article
- In vitro differentiation of mouse embryonic stem cells into inner ear hair cell-like cells using stromal cell conditioned medium.Cell death & disease · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
Abstract
Despite the significant impact of hearing and balance disorders on the general population there are currently no dedicated pharmaceuticals that target the inner ear. Advances in molecular biology and neuroscience have improved our understanding of the inner ear allowing the development of a range of molecular targets that have the potential to treat both hearing and balance disorders. One of the principal advantages of the inner ear is that it is accessible through a variety of approaches that would allow a potential to be delivered locally rather than systemically. This significantly broadens the potential medications that can be developed and opens the possibility of local gene delivery as a therapeutic intervention. Several potential clinical targets have been identified including delivery of neurotrophin expressing genes as an adjunct to cochlear implantation, delivery of protective genes to prevent trauma and the development of strategies for regenerating inner ear sensory cells. In order to translate these potential therapeutics into humans we will want to optimize the gene delivery methodology, dosing and activity of the drug for therapeutic value. To this end we have developed a series of adenovectors that efficiently transduce the inner ear. The use of these gene delivery approaches are attractive for the potential of hair cell regeneration after loss induced by trauma or ototoxins. This approach is particularly suited for the development of molecular therapies targeted at the vestibular system given that no device based therapeutic such a cochlear implant available for vestibular loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.